Can I Take Green Tea Extract (EGCG) with MK-677 (Ibutamoren)?

Taking green tea extract with MK-677 is not established as safe or unsafe as a pair, because nobody has studied the pair. What can be said with more confidence is that each compound carries its own liability, that those liabilities plausibly stack, and that a clinician or pharmacist should be involved before combining them, particularly for anyone with existing liver or metabolic risk factors.

What MK-677 and EGCG Actually Do

MK-677 (ibutamoren) is an orally active ghrelin receptor agonist. It stimulates pulsatile growth hormone (GH) release and raises insulin-like growth factor 1 (IGF-1). It was developed as a Merck research compound and has never received FDA approval; it is sold outside the regulated drug supply as a "research chemical." A randomized trial in older adults (Nass et al., 2008) found that 25 mg/day over two years raised GH and IGF-1 measures and was associated with improvements in some body-composition outcomes [1]. An earlier short-term crossover trial (Chapman et al., 1996) found that daily oral MK-677 significantly increased GH pulse amplitude and IGF-1 concentrations within two weeks in healthy volunteers [2]. Exact effect sizes varied by dosing arm and duration in these trials; readers who need precise figures for a specific dose should consult the primary papers rather than a secondhand percentage.

MK-677 is absorbed orally and has a reported half-life of roughly 4 to 6 hours. Hepatic metabolism, including CYP3A4 activity, plays a role in its clearance.

Green tea extract standardized for EGCG (epigallocatechin gallate) is a widely used supplement, taken for its antioxidant and anti-inflammatory properties and modest effects on fat oxidation and glucose handling. EGCG also interacts with several cytochrome P450 enzymes and with P-glycoprotein, an intestinal transporter, at concentrations achievable with concentrated extracts (as opposed to brewed tea) [3][8].

People stack the two for plausible-sounding reasons: EGCG's antioxidant profile, its mild glucose-lowering effect, and a belief that it offsets MK-677's appetite-stimulating or fluid-retention effects. None of those reasons have been tested as a combined protocol.

Evidence-Status Interaction Assessment

This is not a single risk score. It is a map of what is actually known, what is pharmacologically plausible but unproven, and what remains unstudied, so a reviewing clinician can see exactly where the evidence stops and judgment has to start.

Established, with direct supporting evidence

Pharmacologically plausible, not confirmed for this combination

• EGCG's CYP3A4 inhibition could slow MK-677 clearance and raise its plasma levels. No study has measured MK-677 blood levels with and without concurrent EGCG.
• EGCG's P-glycoprotein inhibition could increase MK-677 oral absorption. This is documented for other P-gp substrates in vitro, not tested for MK-677 specifically [8].
• Hepatic stress from EGCG and from MK-677 could be additive, since both plausibly burden hepatocytes, EGCG through oxidative stress at high concentrations and MK-677 through increased metabolic demand from sustained GH and IGF-1 elevation. This is a mechanistic inference, not a measured effect of co-administration.
• EGCG has been shown to modulate growth-factor receptor signaling (HER3, COX-2) in colon cancer cell lines [9]. Whether this extends to IGF-1 receptor signaling in intact human skeletal muscle, which is the pathway relevant to MK-677 users, has not been tested and should be treated as an open hypothesis, not a finding.

Not established, no direct evidence either way

• No trial, case series, or pharmacokinetic study has evaluated MK-677 and EGCG taken together, at any dose or timing.
• MK-677's own hepatotoxic potential has not been characterized in a controlled trial; what exists is scattered self-reported adverse-event data, which cannot establish incidence or causation.
• There is no established "safe" EGCG dose for someone also taking MK-677. Case-literature dose ranges associated with liver injury exist for EGCG alone, not for EGCG combined with a GH secretagogue.
• A broader search for primary regulatory or trial sources specific to this exact pairing did not surface anything topically relevant beyond the pharmacology and case-report literature already cited here; there is no FDA label for MK-677 because it is not an approved drug, and no supplement label carries interaction data of this kind.

What a clinician or pharmacist should verify before this combination is used

1. Baseline and pre-existing liver disease status, alcohol use, and any other hepatotoxic medications or supplements already in use.
2. Whether the person is on any other CYP3A4 substrate or inhibitor, where an added EGCG effect could compound an existing interaction.
3. Diabetes or pre-diabetes status, given MK-677's glucose-raising tendency and EGCG's opposing but modest glucose-lowering tendency.
4. A monitoring plan with a defined stop rule, not an open-ended combination with no recheck date.

The Hepatotoxicity Overlap

This is the most clinically relevant concern with the pairing, because it is the one place where each compound's separate evidence base points in the same direction.

What the EGCG Evidence Shows

A 2008 systematic safety review commissioned by the US Pharmacopeia (Sarma et al.) evaluated published case reports of liver injury associated with green tea-containing supplements and found a recurring hepatocellular injury pattern, generally at higher concentrated-extract doses than typical brewed tea intake [4]. The NIH LiverTox database discusses green tea extract as an established cause of idiosyncratic liver injury based on this case literature, with a latency period that is often weeks to a few months [5]. A pharmacokinetic study (Chow et al., 2005) found that taking EGCG in a fasted state produced meaningfully higher peak plasma EGCG concentrations than the same dose taken with food, which is one proposed reason concentrated extracts taken on an empty stomach carry more risk than the same dose taken with a meal [6].

There is no single EGCG dose confirmed to be free of risk. Lower doses taken with food appear less risky based on the pharmacokinetics, but "less risky" is not the same as "safe," and no dose-response threshold has been formally established in a controlled trial.

What Is Known About MK-677 and the Liver

MK-677's hepatic safety profile is not well characterized. No large prospective trial has systematically tracked liver enzymes in ibutamoren users over time. Reports outside the peer-reviewed literature, including forum and adverse-event self-reports, describe mild ALT elevations that reportedly resolve after stopping the compound, but this kind of unverified, uncontrolled reporting cannot establish how common the effect is or what causes it. The proposed mechanism, increased hepatic metabolic demand from sustained GH and IGF-1 elevation, is biologically plausible but unproven.

Why Combining Them Raises the Stakes

When two substances that may independently stress the liver are combined, the honest position is that the risk cannot be precisely quantified, not that it is necessarily doubled or additive in a specific proportion. Relevant factors that would shift an individual's risk include:

• Pre-existing liver disease or elevated baseline transaminases
• Concurrent alcohol use or other hepatotoxic medications
• EGCG dose and whether it is taken fasted or with food
• Individual variation in CYP3A4 activity

Anyone using both compounds should treat liver function testing as a required part of the protocol, not an optional add-on.

Pharmacokinetic Interaction: CYP3A4 and P-Glycoprotein

Both MK-677 and EGCG interact with CYP3A4, an enzyme responsible for metabolizing a large share of prescription drugs, and EGCG also inhibits P-glycoprotein, an intestinal transporter that limits oral absorption of certain compounds.

CYP3A4

In vitro work has shown EGCG inhibits CYP3A4 activity at physiologically relevant concentrations [3]. Green tea catechins have also been shown to inhibit cytochrome P450-mediated metabolic pathways in laboratory assays (Muto et al., 2001), though that study examined procarcinogen activation, not a human drug-interaction trial with a CYP3A4 probe drug, and did not involve MK-677 or a comparable secretagogue [7]. Whether EGCG's CYP3A4 effect is strong enough at typical supplement doses to meaningfully slow MK-677 clearance in a live person has not been tested. If it did occur, the expected direction would be higher-than-intended MK-677 exposure, which could intensify known MK-677 effects such as appetite stimulation, fluid retention, and glucose elevation.

P-Glycoprotein

EGCG inhibits P-glycoprotein in vitro, which could theoretically increase the oral absorption of drugs that are P-gp substrates [8]. This has not been confirmed for MK-677 specifically in a human trial.

A Reasonable Precaution, Not a Validated Protocol

Because EGCG's enzyme and transporter effects are believed to peak within the first couple of hours after ingestion and decline over several hours, separating EGCG and MK-677 dosing by at least 4 hours, and avoiding fasted-state EGCG dosing, are reasonable precautions based on the pharmacokinetics of EGCG alone. This is site judgment extrapolated from EGCG's known behavior, not a tested interaction-mitigation protocol for this specific pair.

Pharmacodynamic Considerations: IGF-1 and Metabolism

IGF-1 Signaling

MK-677 raises IGF-1 substantially in published trials, including the Nass 2008 trial where IGF-1 was maintained at the upper end of the young-adult reference range over two years [1]. EGCG has been shown to modulate growth-factor receptor signaling, including HER3 and COX-2 expression, in human colon cancer cell lines [9]. Whether EGCG meaningfully affects IGF-1 receptor signaling in human skeletal muscle, at concentrations achievable from oral supplementation, has not been studied. Treat any claim that EGCG "blunts" MK-677's IGF-1 effect as an unconfirmed hypothesis, not an established finding.

Blood Glucose

MK-677 is associated with increased fasting glucose and reduced insulin sensitivity in short-term trials. EGCG has the opposite tendency: a meta-analysis of 17 randomized trials (Liu et al., 2013) found a small, statistically detectable reduction in fasting glucose with green tea supplementation, an effect of limited clinical size on its own [10]. The two effects may partially offset on the glucose axis specifically, but that offsetting effect does not address the separate hepatotoxicity and CYP3A4 concerns, and glucose management should not be assumed to work reliably in any individual based on population-level averages.

Sleep

MK-677 is associated with increased slow-wave sleep through its effect on nocturnal GH release. A caffeinated green tea extract taken in the evening could work against that benefit, independent of any EGCG-MK-677 interaction, simply because of the caffeine. Decaffeinated EGCG extracts avoid this specific issue.

Monitoring If Both Are Used

No clinical guideline addresses MK-677 plus EGCG specifically, because no guideline body endorses MK-677 for general use in the first place. The monitoring approach below is extrapolated from general hepatotoxicity-monitoring practice and standard drug-induced liver injury criteria, not a validated protocol for this pair.

Before Starting

• Complete metabolic panel (ALT, AST, alkaline phosphatase, bilirubin) to establish a baseline
• Fasting glucose and HbA1c, given MK-677's glucose effect
• IGF-1 level, to have a pre-treatment reference point

While Continuing

Repeat liver function tests at 4 and 8 weeks. Prospective drug-induced liver injury research commonly uses ALT or AST elevations above three times the upper limit of normal, especially combined with elevated bilirubin, as a threshold warranting discontinuation and clinical evaluation (Chalasani et al., 2008) [11]. That threshold comes from general DILI research, not a study of this specific combination, but it is a reasonable stop rule in the absence of anything more specific.

Practical Precautions

• No EGCG dose is confirmed safe in combination with MK-677; if used, lower doses of standardized extract taken with food, not fasted, reduce peak plasma EGCG concentrations
• Separate MK-677 and EGCG dosing by at least 4 hours
• Avoid stacking additional CYP3A4 inhibitors (grapefruit juice, azole antifungals, certain SSRIs) on top of this pair
• Avoid alcohol, which independently burdens hepatic pathways that both compounds may also stress

Who Should Avoid This Combination

Reasonable Contraindications

• Existing liver disease of any cause, including fatty liver disease or elevated baseline transaminases
• Concurrent use of other hepatotoxic agents, including anabolic steroids, high-dose acetaminophen, valproate, or azole antifungals
• Diabetes managed with insulin or sulfonylureas, given MK-677's glucose-raising effect
• Age under 18, since GH secretagogues are not appropriate in someone whose growth plates have not fused

Situations That Warrant Extra Caution

• Low body weight or low metabolic reserve, particularly in older adults
• A personal or family history of liver cancer, given theoretical concerns about sustained IGF-1 elevation and hepatic IGF-1 receptor activity
• Use of hormonal contraceptives, which independently affect CYP3A4 activity

These are reasonable clinical precautions based on each compound's individual risk profile, not conclusions from a study of the combination itself.

What the Liver-Injury Literature Says About Green Tea Specifically

Research on drug- and supplement-induced liver injury, including DILIN registry analyses, describes green tea extract-associated liver injury as typically hepatocellular in pattern, with a latency period that has ranged from weeks to several months in published case series (Navarro et al., 2014) [12]. A separate paper focused specifically on green tea supplement hepatotoxicity concluded that concentrated extracts deliver catechin doses well above what is achievable through drinking brewed tea, and cautioned that the safety of tea as a beverage does not automatically transfer to concentrated supplement form (Bonkovsky, 2006) [13]. Neither of these sources discusses MK-677 or GH secretagogues; they establish the hepatotoxicity side of this discussion, not the interaction itself.

Does Any Evidence Support Using Them Together?

No randomized trial, pharmacokinetic study, or case series has evaluated MK-677 and EGCG as a combined protocol. Absence of evidence for harm is not evidence of safety, and the same is true in reverse: absence of a reported disaster does not mean the combination has been vetted. For the goals people usually have in mind with this stack (lean mass preservation, recovery, fat loss), both individual evidence bases are open to question on their own terms, and combining them adds interaction uncertainty on top of that. Diet, resistance training frequency, sleep, and protein intake have a substantially stronger and safer evidence base for the same goals.